ABSCI CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
ABSCI CORP (ABSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $3.10 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.13, a 6.10% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.95, a 13.90% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.59, a 30.38% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.72, a 45.13% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $3.04, a 8.16% decline from fiscal 2024.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $3.31, a 17.04% decline from fiscal 2023.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $3.99, a 23.56% decline from fiscal 2022.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $5.22, a 143.93% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.10 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $3.13 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $3.04 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $3.05 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $2.83 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $2.95 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $3.31 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $3.12 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $3.10 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $2.59 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $3.99 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $3.93 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $4.13 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $3.72 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $5.22 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $5.82 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $4.60 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $6.78 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $2.14 10-K · filed 2022-03-22 | |||
| 2021-09-30 | $1.75 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $1.10 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |